Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MC5R | P33032 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MC1R | Q01726 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25373656 | 0.93 | SMN1; SMN2 (0.50) | L3MBTL1KDM4ESMN1; SMN2MC5RMAPK1 | |
| SCHEMBL5569292 | 0.84 | L3MBTL1 (0.62) | L3MBTL1KDM4ESMN1; SMN2CHRM2MEN1 | |
| SCHEMBL6008064 | 0.82 | MC5R (0.70) | L3MBTL1MC5RMAPK1MC1RMAPT | |
| SCHEMBL9777455 | 0.81 | CHRM2 (0.61) | L3MBTL1KDM4ESMN1; SMN2CHRM2MEN1 | |
| SCHEMBL29438821 | 0.80 | CHRM2 (0.70) | L3MBTL1KDM4ESMN1; SMN2CHRM2MEN1 | |
| SCHEMBL230222 | 0.80 | CHRM2 (0.70) | L3MBTL1KDM4ESMN1; SMN2CHRM2MEN1 | |
| SCHEMBL28911912 | 0.80 | ADRA2A (0.53) | L3MBTL1SMN1; SMN2MAPK1MAPTHPGD | |
| SCHEMBL317984 | 0.78 | CHRM2 (0.68) | L3MBTL1KDM4ESMN1; SMN2CHRM2MEN1 | |
| SCHEMBL25211342 | 0.78 | CHRM2 (0.68) | L3MBTL1KDM4ESMN1; SMN2CHRM2MEN1 | |
| SCHEMBL18493706 | 0.78 | CHRM2 (0.68) | L3MBTL1KDM4ESMN1; SMN2CHRM2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-01 | — | — | US | disclosed |
| EP-4469438-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136594-A1 | COMPOUNDS AND METHODS OF USE | CNKSR1, UGT1A1, REV1 | L3MBTL1 4699/4885KDM4E 1639/4885SMN1; SMN2 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.